Ensaios Clínicos em Fase de Recrutamento

Atualmente, estão em fase de recrutamento para realização no Hospital da Luz os seguintes ensaios clinicos:

  • Ensaios clínicos na área da diabetes

    • Ensaio clínico FIDELIO

    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000990-11/PT

    • Ensaio clínico FIGARO

    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000950-39/PT

  • Ensaios clínicos na área da esclerose múltipla

    • Ensaio Clínico PLENO

    Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000434-21/PT

  • Ensaios clínicos na área do adenocarcinoma do pâncreas

    • Ensaio clinico CanStem111P

    “A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma”

    Mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004359-57/PT

    • Ensaio Clínico CanStem111P

    A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004359-57/PT

  • Ensaios clínicos na área do carcinoma da mama

    •  Ensaio clínico OLYMPIA

    A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003839-30/PT

    • Ensaio clínico PALLAS:

    A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005181-30/PT

     

     

     

     

  • Ensaios clínicos na área do carcinoma da próstata

    • Ensaio clínico ARAMIS

    A multinational, randomized, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer

    Para mais informações:
    https://clinicaltrials.gov/ct2/show/NCT02200614?term=ARAMIS&rank=2

  • Ensaios clínicos na área do carcinoma do pulmão

    • Ensaio clínico M16-298 MERU

    “A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003503-64/PT

    • Ensaio clínico M16-289 TAHOE

    “A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003726-17/PT

     

  • Ensaios clínicos na área da insuficiência cardíaca

    • Ensaio Clínico GALACTIC-HF

    A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002299-28/PT

    • Ensaio clínico LCZ696D2302

    A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003410-28/PT

     

     

  • Ensaios clínicos na área do tromboembolismo pulmonar

    • Ensaio clínico Hot PE

    “Home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban: prospective management trial”

    Para mais informações:
    https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001657-28/PT

     

Se estiver interessado em saber mais sobre algum dos ensaios clínicos referidos, poderá enviar um e-mail para ensaiosclinicos.lisboa@hospitaldaluz.pt e a equipa do Centro de Investigação Clínica do Hospital da Luz entrará em contacto consigo.

O envio deste e-mail não é garantia da participação num ensaio clínico.